World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT00552682
Date of registration: 31/10/2007
Primary sponsor: Germans Trias i Pujol Hospital
Public title: Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+
Scientific title: Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+
Date of first enrolment: January 2007
Target sample size: 10
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT00552682
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment  
Countries of recruitment
Contacts
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Patients aged 18 years old and more. Age +18 years old.

2. Documented HIV-1-infection.

3. Former diagnosis of fibromialgy.

4. History of good compliance with visit schedule and medication intake.

5. Patients voluntary signed the informed consent.

Exclusion Criteria:

1. Pregnant or breast-feeding females

2. Suspicion of intolerance to duloxetine.

3. History of any clinical condition that, in the Investigator's criteria, could
potentially reoccur with the suggested change of therapy (sarcoma, lymphoma, etc).

4. Concomitant condition that could mimic fibromialgy (lupus, endocrine diseases,
muscular diseases, multiple sclerosis)

5. or Acute illness within 15 days prior to the inclusion

6. Patients with major depressive disorder with psychotic symptoms, major depressive
disorder melancholic type or bipolar disorder. Patients with other depressive
disorders can be included (dysthymic disorder and depressive disorder NOS)

7. Anorexia or nervous bulimia

8. History or suspected drug or alcohol abuse.

9. Glaucoma

10. History of heart disease including cardiac arrhythmias

11. Severe obesity (body mass index > 45).

12. Concomitant medication with IMAOS, cimetidine or quinolonas

13. Patients with hepatic or renal serious failure (Creatinin clearance <30 ml/min)

14. Patients with Hypericum perforatum as a concomitant treatment.



Age minimum: 18 Years
Age maximum: 70 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Fibromyalgia
HIV-1 Infection
Intervention(s)
Drug: Duloxetine 60 mg, QD
Primary Outcome(s)
Variation in pain measured using the Brief Pain Inventory questionnaire in both branches of the study [Time Frame: Time frame: basal visit, weeks 4, 12, 24, 36 and 48]
Secondary Outcome(s)
Assess differences in Beck Depression Inventory (BDI) questionnaire scale score. [Time Frame: basal visit, weeks 12, 24 and 48]
Assess differences in Profile of Mood States - Forma A (POMS-A) questionnaire scale score. [Time Frame: basal visit, weeks 12, 24 and 48]
Assess differences in Short-Form 36 Health Survey (SF-36) questionnaire scale score. [Time Frame: basal visit, weeks 12, 24 and 48]
Assess the percentage of patients that leave duloxetine due to intolerance or toxicity. [Time Frame: basal visit, weeks 4, 12, 24, 36 and 48]
Assess, if possible, pharmacokinetic profile of duloxetine and determine interaction with antiretroviral drugs. [Time Frame: basal visit, weeks 4, 12, 24, 36 and 48]
Secondary ID(s)
FIBROHIV
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Fundacio Lluita Contra la SIDA
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history